US · CAPR
Capricor Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- capricor.com
Price · as of 2024-12-31
$30.91
Market cap 1.28B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.81 | -22.97% |
| Intrinsic Value(DCF) | $6.72 | -78.26% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $3.41 | -88.98% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $310.00 | ||||
| 2011 | $265.00 | $0.00 | $0.00 | ||
| 2012 | $40.00 | $7,886.55 | $33.59 | $0.00 | $1,654.03 |
| 2013 | $120.00 | $377.78 | $8.92 | $0.00 | $0.00 |
| 2014 | $71.90 | $1,701.24 | $1,142,674.23 | $0.00 | $0.00 |
| 2015 | $21.60 | $10,057.25 | $119,165.20 | $0.00 | $6.96 |
| 2016 | $28.30 | $41.39 | $161.19 | $0.00 | $68.85 |
| 2017 | $18.60 | $117.31 | $0.39 | $10.08 | $0.00 |
| 2018 | $4.60 | $325.33 | $0.00 | $0.00 | $142.93 |
| 2019 | $1.13 | $216.51 | $0.00 | $0.00 | $61.65 |
| 2020 | $5.18 | $25.37 | $0.82 | $0.00 | $50.92 |
| 2021 | $4.18 | $21.73 | $0.35 | $0.00 | $10.37 |
| 2022 | $4.64 | $165.77 | $0.00 | $0.00 | $0.00 |
| 2023 | $5.89 | $382.02 | $6,630.45 | $0.00 | $0.00 |
| 2024 | $12.81 | $23.81 | $3,186.27 | $0.00 | $3.41 |
AI valuation
Our deep-learning model estimates Capricor Therapeutics, Inc.'s (CAPR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.81
- Current price
- $30.91
- AI upside
- -22.97%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.72
-78.26% upside
Graham-Dodd
—
— upside
Graham Formula
$3.41
-88.98% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CAPR | Capricor Therapeutics, In… | $30.91 | 1.28B | -23% | -78% | — | -89% | -11.15 | 3.10 | 20.26 | -7.32 | -28.92 | 3.10 | -124.37% | -191.13% | -181.71% | -48.16% | 442.17% | -35.31% | 0.01 | — | 7.77 | 7.70 | 0.24 | 3855.00% | -1155.00% | 5025.00% | -9.21% | -1.90 | 431.47% | 0.00% | 0.00% | 0.00% | -7.07 | -7.25 | 13.52 | 9.49 |
| ACHV | Achieve Life Sciences, In… | $4.56 | 242.75M | — | — | — | — | -2.53 | 4.82 | — | -2.04 | — | 5.33 | 0.00% | — | — | -409.51% | 2085.90% | -137.33% | 0.48 | -17.92 | 5.46 | 5.14 | 0.07 | -1733.00% | — | 2151.00% | -29.56% | -4.46 | 1589.43% | 0.00% | 0.00% | 3.93% | -1.95 | -2.56 | — | -6.45 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| CABA | Cabaletta Bio, Inc. | $3.32 | 319.6M | — | — | — | — | -0.79 | 0.60 | — | 0.51 | -1.89 | 0.60 | 0.00% | — | — | -59.64% | -6352.34% | -52.82% | 0.10 | -167.30 | 6.15 | 6.05 | 1.35 | 4182.00% | — | 6674.00% | -98.71% | -3.26 | -4590.51% | 0.00% | 0.00% | 0.00% | 0.45 | 0.63 | — | -2.29 |
| EDIT | Editas Medicine, Inc. | $2.20 | 214.76M | +883% | +13% | — | +6,172% | -0.60 | 1.05 | 4.38 | 0.40 | -1.40 | 1.05 | 100.00% | -777.22% | -733.72% | -98.10% | 1925.86% | -56.40% | 0.26 | — | 3.75 | 3.71 | 0.41 | 4257.00% | -5864.00% | 6005.00% | -154.71% | -2.72 | 1680.16% | 0.00% | 0.00% | 15.11% | 0.37 | 0.43 | -2.89 | -7.20 |
| IMMP | Immutep Limited | $2.80 | 412.14M | +523% | -76% | — | — | -5.97 | 2.55 | 72.72 | -3.80 | -35.82 | 2.69 | -1117.55% | -2506.49% | -1218.02% | -36.88% | -1019.26% | -34.27% | 0.01 | — | 11.69 | 10.17 | 1.05 | 1667.00% | 3128.00% | 7368.00% | -16.93% | -4.86 | -500.64% | 0.00% | 0.00% | 0.00% | -1.89 | -3.84 | 47.33 | 10.94 |
| LXEO | Lexeo Therapeutics, Inc. … | $7.18 | 524.05M | — | — | — | — | -0.87 | 0.73 | — | 0.27 | -3.62 | 0.73 | 0.00% | — | — | -85.37% | -2362.17% | -68.58% | 0.08 | -927.77 | 5.52 | 5.32 | 0.26 | 2410.00% | — | 3683.00% | -95.11% | -3.55 | -1823.16% | 0.00% | 0.00% | 0.02% | 0.24 | 0.32 | — | -2.49 |
| PRQR | ProQR Therapeutics N.V. | $1.59 | 167.5M | +4,852% | +2,420% | — | — | -4.80 | 1.50 | 7.05 | -0.05 | — | 1.50 | 100.00% | -161.18% | -146.86% | -41.35% | 56.30% | -17.34% | 0.19 | -28.29 | 3.95 | 3.84 | 5.48 | -286.00% | 19022.00% | -28740.00% | -28.37% | -0.94 | 70.36% | 0.00% | 0.00% | 16.97% | -0.04 | -0.03 | 0.06 | -2.22 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| VNDA | Vanda Pharmaceuticals Inc… | $8.91 | 526.65M | +158% | -50% | — | — | -2.18 | 1.47 | 2.23 | -1.65 | -0.20 | 2.29 | 93.96% | -69.95% | -102.02% | -50.93% | -119.87% | -38.51% | 0.04 | — | 2.39 | 2.19 | 0.52 | 106875.00% | 872.00% | 57976.00% | -22.94% | -0.75 | -87.57% | 0.00% | 0.00% | 0.00% | -1.52 | -2.08 | 1.07 | 0.57 |
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
- CEO
- Linda Marbán
- Employees
- 160
- Beta
- 0.40
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.72 ÷ $30.91) − 1 = -78.26% (DCF, example).